Hem › Steatotisk leversjukdom › Colorado
Kliniska studier för Steatotisk leversjukdom i Colorado
6 studier för Steatotisk leversjukdom söker deltagare vid platser i Colorado.
Städer i Colorado
Officiell studietext (engelska)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Littleton
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Littleton
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06318169A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- University of Colorado Anschutz Medical Campus, Aurora
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 25 sep. 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- University of Colorado Anschutz Medical Campus, Aurora
- South Denver Gastroenterology, Englewood
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Aurora
- Akero Clinical Study Site, Colorado Springs
- Akero Clinical Study Site, Englewood
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 21 sep. 2026 · NCT06528314A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Colorado Springs
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 27 juli 2026 · NCT07221227Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.